Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416839639> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2416839639 endingPage "103" @default.
- W2416839639 startingPage "S99" @default.
- W2416839639 abstract "To review the current information available from the European Organization for Research and Treatment of Cancer (EORTC) programs on the use of interleukin (IL)-2 in stage IV melanoma patients.A database from 631 patients treated within 27 trials with high-dose IL-2-based regimens was compiled to develop hypotheses and valid stratification factors for randomized trials. Subsequently, 126 patients were enrolled in a trial evaluating interferon alfa (IFN-alpha) and IL-2 with or without cisplatin, and 325 patients were enrolled in an ongoing EORTC trial (18951) to evaluate dacarbazine, cisplatin, and IFN-alpha, with or without IL-2.The database suggests long-term survival rates of 23% and a 5-year survival rate of 13% for patients receiving a combination of IFN-alpha and IL-2 with or without chemotherapy. The addition of chemotherapy improved response rate but not survival. The first randomized trial testing the role of cisplatin in a chemoimmunotherapy regimen for advanced melanoma revealed a palliative effect for cisplatin but no survival benefit. The current trial (EORTC 18951), which is testing the impact of IL-2 on survival, is still immature. In the translational research program, we have evidence that patients in continuous complete remission after IL-2-based treatment have evidence of residual disease by polymerase chain reaction assay and, at the same time, melanoma-reactive T cells are present in the peripheral blood.Mature results defining the role and, to some extent, the mechanism of IL-2 in advanced melanoma are emerging." @default.
- W2416839639 created "2016-06-24" @default.
- W2416839639 creator A5027568073 @default.
- W2416839639 creator A5066640097 @default.
- W2416839639 date "2000-02-01" @default.
- W2416839639 modified "2023-09-23" @default.
- W2416839639 title "The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program." @default.
- W2416839639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10685668" @default.
- W2416839639 hasPublicationYear "2000" @default.
- W2416839639 type Work @default.
- W2416839639 sameAs 2416839639 @default.
- W2416839639 citedByCount "7" @default.
- W2416839639 countsByYear W24168396392013 @default.
- W2416839639 countsByYear W24168396392016 @default.
- W2416839639 crossrefType "journal-article" @default.
- W2416839639 hasAuthorship W2416839639A5027568073 @default.
- W2416839639 hasAuthorship W2416839639A5066640097 @default.
- W2416839639 hasConcept C121608353 @default.
- W2416839639 hasConcept C126322002 @default.
- W2416839639 hasConcept C143998085 @default.
- W2416839639 hasConcept C168563851 @default.
- W2416839639 hasConcept C203014093 @default.
- W2416839639 hasConcept C2776178377 @default.
- W2416839639 hasConcept C2776283816 @default.
- W2416839639 hasConcept C2776694085 @default.
- W2416839639 hasConcept C2777658100 @default.
- W2416839639 hasConcept C2777701055 @default.
- W2416839639 hasConcept C2778239845 @default.
- W2416839639 hasConcept C2780790343 @default.
- W2416839639 hasConcept C2780964509 @default.
- W2416839639 hasConcept C2781228144 @default.
- W2416839639 hasConcept C2781413609 @default.
- W2416839639 hasConcept C2909179924 @default.
- W2416839639 hasConcept C502942594 @default.
- W2416839639 hasConcept C535046627 @default.
- W2416839639 hasConcept C71924100 @default.
- W2416839639 hasConceptScore W2416839639C121608353 @default.
- W2416839639 hasConceptScore W2416839639C126322002 @default.
- W2416839639 hasConceptScore W2416839639C143998085 @default.
- W2416839639 hasConceptScore W2416839639C168563851 @default.
- W2416839639 hasConceptScore W2416839639C203014093 @default.
- W2416839639 hasConceptScore W2416839639C2776178377 @default.
- W2416839639 hasConceptScore W2416839639C2776283816 @default.
- W2416839639 hasConceptScore W2416839639C2776694085 @default.
- W2416839639 hasConceptScore W2416839639C2777658100 @default.
- W2416839639 hasConceptScore W2416839639C2777701055 @default.
- W2416839639 hasConceptScore W2416839639C2778239845 @default.
- W2416839639 hasConceptScore W2416839639C2780790343 @default.
- W2416839639 hasConceptScore W2416839639C2780964509 @default.
- W2416839639 hasConceptScore W2416839639C2781228144 @default.
- W2416839639 hasConceptScore W2416839639C2781413609 @default.
- W2416839639 hasConceptScore W2416839639C2909179924 @default.
- W2416839639 hasConceptScore W2416839639C502942594 @default.
- W2416839639 hasConceptScore W2416839639C535046627 @default.
- W2416839639 hasConceptScore W2416839639C71924100 @default.
- W2416839639 hasLocation W24168396391 @default.
- W2416839639 hasOpenAccess W2416839639 @default.
- W2416839639 hasPrimaryLocation W24168396391 @default.
- W2416839639 hasRelatedWork W204022592 @default.
- W2416839639 hasRelatedWork W2057024276 @default.
- W2416839639 hasRelatedWork W2058508302 @default.
- W2416839639 hasRelatedWork W2081853274 @default.
- W2416839639 hasRelatedWork W2152169833 @default.
- W2416839639 hasRelatedWork W2356441863 @default.
- W2416839639 hasRelatedWork W2394601029 @default.
- W2416839639 hasRelatedWork W2397644467 @default.
- W2416839639 hasRelatedWork W2416839639 @default.
- W2416839639 hasRelatedWork W2420955837 @default.
- W2416839639 hasVolume "6 Suppl 1" @default.
- W2416839639 isParatext "false" @default.
- W2416839639 isRetracted "false" @default.
- W2416839639 magId "2416839639" @default.
- W2416839639 workType "article" @default.